Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8417412 | 0.98 | DPP7 (0.47) | DPP7LMNAGAAFDPSL3MBTL1 | |
| SCHEMBL10509650 | 0.85 | DPP7 (0.42) | DPP7LMNAGAAFDPSL3MBTL1 | |
| SCHEMBL11173567 | 0.85 | DPP7 (0.45) | DPP7LMNAGAAFDPS | |
| SCHEMBL3969170 | 0.82 | DPP7 (0.48) | DPP7LMNAGAAFDPS | |
| Ammonia Solution, Strong SCHEMBL10713045 | 0.80 | DPP7 (0.47) | DPP7LMNAGAAFDPS | |
| SCHEMBL5824292 | 0.79 | DPP7 (0.34) | DPP7LMNAFDPSL3MBTL1 | |
| SCHEMBL2353452 | 0.79 | CPN1 (0.31) | — | |
| SCHEMBL10724095 | 0.74 | DPP7 (0.43) | DPP7LMNAGAA | |
| SCHEMBL10730362 | 0.74 | DPP7 (0.43) | DPP7LMNAGAA | |
| SCHEMBL6243407 | 0.70 | DPP7 (0.42) | DPP7LMNAGAAFDPSL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088776-B2 | Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2307401-A2 | ANTINEOPLASTIC DERIVATIVES OF 4-OXO-1,4-DIHYDRO-QUINOLINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2011-04-13 | — | — | EP | disclosed |